Start with the question. Find the right medical device insight fast.
This page is now the first layer of the insight experience: a searchable, categorized index of our public guides, articles, samples, and tools for market entry and lifecycle review.
Layer 1: Search and category browsing. This release delivers that.
Layer 2: Guided question search across the insight library.
Layer 3: Product-specific answers inside a Product ID workspace after signup.
Find the right insight by question, task, and jurisdiction
Search across our indexed insight pages, guides, samples, and tools. This first layer is for general discovery. Product-specific questions still need a Product ID workspace.
Health Canada licence handoff checklist before consultant review
If your founder or first RA/QA lead needs to hand a Class II, III, or IV licence package to a consultant, start with the official-source checklist: intended purpose, class clues, application type, REP setup, evidence pack contents, fees, and annual right-to-sell implications.
MDL vs MDEL in Canada: what founders should sort out before a consultant call
If your team keeps asking whether a Canada launch needs a Medical Device Licence, a Medical Device Establishment Licence, or both, start with the official distinction: device class, company activity, annual review, fee type, and the exact questions to carry into consultant review.
FDA 510(k) consultant handoff checklist before you spend the first review hour
If your founder or first RA/QA hire is about to brief a U.S. consultant, start with the official-source package: intended use, candidate product code and class clues, predicate shortlist, comparison table, draft 510(k) content map, eSTAR readiness, and fee-cover-sheet questions.
FDA product code vs device class: what to sort out before a consultant call
If your team keeps mixing up product code, regulation number, device class, and submission type, start with the official FDA distinction: intended use first, then classification search, then similar-device evidence, then the question of whether a formal 513(g) request is worth paying for.
What to gather before an FDA 513(g) request
If public FDA classification research still leaves your team unsure what generic type, class, or marketing-submission bucket may apply, start with the official-source 513(g) preparation packet: intended use, device description, draft claims, similar-device evidence, exact questions, fee context, and response-window planning.
U.S. FDA market-entry research guide
An answer-first guide for what to collect before a U.S. Food and Drug Administration market-entry review or consultant handoff.
Health Canada Medical Device Licence Evidence Map
A structured evidence map for what to gather around a Canada product-family licence review.
Medical Device Product Evidence Map tool
An interactive tool for seeing what evidence areas matter before a market-entry or consultant review.
FDA Market-Entry Product ID sample
A synthetic sample of what a Product ID workspace can organize before formal U.S. market-entry planning.
Post-clearance review point sample
A synthetic sample of reusable lifecycle review structure after clearance or licence is already in place.
The RA/QA Gap Is Not Evidence Collection. It Is Decision Reuse.
Why similar-device signals need to become structured review points, not just archived narratives or attachments. A four-layer model RA/QA teams can use to turn external signals and internal product events into inspection-ready decisions, with an infusion pump example.
A QMS Is Required. But Is It Learning?
When a complaint, supplier change, or peer-device recall lands on a reviewer's desk, do all the prior reviews on the same failure mechanism, the same component, and the same risk area come back into the reviewer's pane automatically? Or does the reviewer have to remember to look, hunt across folders, and rebuild the rationale by hand? This article looks at the QMS gap between storing a record and retrieving it on the next event.
Why Medical Device RA/QA Teams Need a Product-Specific Compliance Digital Twin
QMS records process completion; a product-specific compliance digital twin records whether compliance work is producing better product-level outcomes. This explainer covers what the digital twin is, how the Product Review Workspace exposes it, and why RA/QA leaders need it now — alongside the QMS, not instead of it.
Anatomy of a Review-Ready PMS Evidence Pack for Infusion Pump Reviews
A walkthrough of what goes into a portable PMS evidence pack for infusion pump reviews — the eight sections, the table of contents, and how the decision rationale is captured. Review support; RA/QA owns the final decision.
Product Review Workspace for Medical Device RA/QA Teams
When a product event triggers a review question — a complaint, repair trend, supplier issue, software signal, field event, or change question — RA/QA teams still have to apply general standards and SOPs to their specific device. The Product Review Workspace turns general guidance into product-specific review points, candidate workflow paths, and an Evidence Record Draft.
MDALL, MDEL, Recalls, and Safety Alerts: What Canadian Device Distributors Should Keep in the Product File
Canadian distributors and importers often want more than a supplier brochure in the product file. Here's what MDALL, MDEL, recalls, and safety alerts each tell you, what to capture in the file, and what supplier follow-up questions naturally fall out of the check.
Before Reordering a Medical Device SKU, What Public Records Should You Check?
Importers, distributors, procurement, supplier-quality, and RA/QA teams often want a dated public-source record before placing a PO or reordering a medical device SKU. Here's what FDA and Health Canada publish, what a useful pre-PO snapshot looks like, and what the check is not.
Management review is next week. ISO 13485 5.6 requires external signal data as input. Your team hasn't gathered it yet, and you're staring at a blank slide for the board report on risk exposure and co
Here's what's happening right now: There were 10,384 new regulatory signals today, including 10,360 FDA Adverse Event Reports (MAUDE/MDRs) and 22 Health Canada mdl entries. Notably, Health Canada issued 2 new recalls: Auro-Canagliflozin for incorrect DIN labeling and LUXA-D for a foreign product in a capsule, both flagged for product safety. For your management review under QMSR and 21 CFR 820, this data isn't just noise—it's critical for quantifying risk exposure and benchmarking against compe
Complaint trends are rising for one product family but you can't tell if it's an industry-wide issue or yours alone. You're reviewing your CAPA dashboard, trying to prioritize investigations against l
Here's what's happening right now: 10,384 new regulatory signals hit the system today. That includes 10,360 new FDA adverse event reports (MAUDE/MDRs) and 2 new Health Canada recalls. One recall involves incorrect DIN labeling on a blister card (Auro-Canagliflozin), and another involves a foreign product in a capsule batch (LUXA-D). For your CAPA prioritization and complaint handling, notice the pattern in the MDRs: multiple reports for infusion set tubing detachment events and software/app mal
A competitor's device just got recalled. Your auditor will ask: 'How did you evaluate whether this affects your products?' You're reviewing the alert, knowing it could trigger a supplier audit or requ
Here's what's happening right now: 2 new Health Canada recalls were issued this week, both for product safety issues. Auro-Canagliflozin has affected lots with incorrect DIN labeling on blister cards, and LUXA-D has a capsule containing a foreign product in the batch. This adds to 10,360 new FDA Adverse Event Reports (MAUDE/MDRs) and 22 new Health Canada mdl signals today, totaling 10,384 new regulatory signals. For RA Managers focused on audit preparedness and post-market surveillance, these s
Daily Signal Insight — Apr 01, 2026: Software and supply chain failures dominate post-market signals, requiring proactive QMSR evidence.
By TrueMedDevice Team · Apr 01, 2026 · 5 min read | Today's 10,384 signals reveal that software-related malfunctions and supply chain quality issues are the primary drivers of post-market risk, demanding immediate cross-functional action to build audit-ready evidence.
When a Competitor Knee-System Recall Exposes a Component Tolerance Problem, What Should an Orthopedic Team Actually Do?
An OrthAlign knee-system recall does not prove the same defect in another product, but it does justify a documented orthopedic workflow assessment instead of premature closure.
When a Competitor’s Surgical Instrument Is Recalled for Supplier Weld Failures, What Should Your Team Actually Do?
If you manufacture electrosurgical instruments or any device with welded metal components from external suppliers, this recall creates a specific question: could the same supplier validation gap exist in your supply chain?
When a Competitor’s Surgical Instrument Is Recalled for Supplier Weld Failures, What Should Your Team Actually Do?
If you manufacture electrosurgical instruments or any device with welded metal components from external suppliers, this recall creates a specific question: could the same supplier validation gap exist in your supply chain?
The board wants a single number for regulatory risk exposure. Your quality team gives you a spreadsheet with 200 rows and no summary. You're staring at disparate data points, trying to distill it into
Here's what's happening right now: As of March 29, 2026, there are 26,202 new regulatory signals in the market. This includes 26,000 new FDA Adverse Event Reports (MAUDE/MDRs) and 202 new Health Canada mdl entries. These numbers represent the raw volume of post-market activity you need to contextualize for risk assessment and compliance reporting. For a VP Quality/Regulatory, this data isn't just noise—it's critical for quantifying risk exposure and informing your board. The surge in adverse ev
Root cause analysis keeps landing on the same categories: software, components, design. But which one actually needs CAPA resources first? You're reviewing this week's nonconformance trends, trying to
Here's what's happening right now: 26,202 new regulatory signals hit the system today. Among the high-priority FDA Adverse Event Reports, we see multiple malfunctions in insulin pumps (Tandem Diabetes Care's t:slim X2 with Control-IQ Technology) and video systems (Shirakawa Olympus's Visera Video System Center and Camera Head). The Olympus investigation specifically noted "a root cause could not be identified" with the most probable cause traced to "component failure." For CAPA prioritization u
New QMSR requirements changed the documentation expectations. Your procedures reference the old QSR. The gap analysis hasn't started, and you're prioritizing which updates will impact your next audit
Here's what's happening right now: Today alone, we tracked 26,202 new regulatory signals, including 26,000 new FDA Adverse Event Reports (MAUDE/MDRs) and 202 new Health Canada mdl entries. This volume underscores the critical need for robust post-market surveillance systems that align with updated QMSR and ISO 13485:2016 frameworks. For RA Managers focused on audit preparedness and QMSR compliance, this data signals a heightened focus on documentation and risk management. The surge in adverse e
Daily Signal Insight — Mar 29, 2026: Third-party servicing gaps and software failures dominate post-market risk signals.
By TrueMedDevice Team · Mar 29, 2026 · 5 min read | Today's 26,202 signals reveal systemic quality control breakdowns in third-party servicing and persistent software-related malfunctions in connected devices.
A labeling recall hit a competitor using the same contract packager. Your labeling uses the same supplier. Is a proactive review justified? You're weighing the risk of a supplier-driven CAPA against t
Here's what's happening right now: 35 new FDA enforcement actions were issued this week. Among them, a recall for the Penner Pacific Bathing Spa due to missing UDI labeling, and multiple recalls for the Raz Mobile Shower Commode Chair series stemming from a vendor modification that led to improper installation of seat brackets. These signals highlight immediate supplier and labeling risks. For Operations Managers focused on 21 CFR 820.50 supplier controls, this data underscores a critical patte
Your competitor just announced a voluntary recall. The CEO asks: 'Are we exposed to the same issue?' You have 2 hours to answer. This is the reality of modern post-market surveillance, where vendor ch
Here's what's happening right now: 35 new FDA enforcement actions were published this week. Among them, a critical pattern emerges: 5 distinct models of Raz Mobile Shower Commode Chairs (Z300, Z333, Z360, Z200, Z100) were recalled due to a vendor modification causing improper seat bracket engagement. Simultaneously, GEM Premier 5000 systems face Process Control Solution Not Detected errors in their PAK cartridges, with two separate recalls (Part No. 00055415008 and 00055360004) highlighting the
You're preparing a 510(k) submission and your predicate device was just recalled. Does your submission strategy need to change? Your design inputs and risk analysis now have a critical new data point
Here's what's happening right now: 35 new FDA enforcement actions were issued today. While the specific device categories aren't detailed in today's signal, this volume indicates active regulatory scrutiny across the medical device landscape. For design engineers, this means your predicate device selection process just got more complex. A recall on your chosen predicate directly impacts your 510(k) substantial equivalence argument and requires immediate updates to your design history file under
Pulse Oximeter Regulatory Landscape: Recalls, 510(k) Clearances, and Risk Signals
Pulse oximeters are among the most widely used medical monitoring devices, yet they are associated with multiple regulatory events. This article analyzes the regulatory landscape including 510(k) clearances, recall trends, MAUDE data, and what RAQA teams should monitor.
Your DHF Is Not a Jira Board: Design Controls That Survive FDA Inspection
A Jira board is not a DHF. Email threads are not design reviews. Learn the 10-step design control workflow, QMSR changes, and how to build a Design History File that survives FDA inspection.
Correction, Removal, or Recall? How to Navigate 21 CFR 806 When Your Device Has a Field Problem
Engineering finds a field problem. Is it a correction, removal, or recall? Learn the 21 CFR 806 decision tree, health hazard evaluation process, and what happens when you miss the 10-day reporting window.
Why Your CAPA System Fails Without Trending: How to Catch Systemic Problems Before Auditors Do
Three CAPAs. Same root cause. No trending analysis. Major nonconformity. Learn why CAPA trending is mandatory, what auditors look for, and the 10-step workflow that prevents repeat findings.
Stop Using RPN for Safety Risk: Why ISO 14971 Rejected Detection and What Auditors Actually Want
The most common mistake in medical device risk management: using FMEA Risk Priority Numbers for ISO 14971 risk evaluation. Here is why Detection is not a risk factor, what auditors look for, and what real FDA enforcement data shows.
Manufacturing nonconformance rates ticked up this quarter. Is it your process, your supplier, or an industry-wide material problem? You're reviewing CAPA data, trying to pinpoint whether to tighten in
Here's what's happening right now: 391 new FDA recalls were issued this week, with a significant cluster in convenience kits used for dialysis maintenance. Specific examples include Medline's ADD A CATH DIALYSIS KIT (SKU ECVC8415A) and Centurion's CENTRAL LINE INSERTION TRAY (SKU DT19810), where silicone seal failures in Tego Connectors are causing occluded fluid paths and therapy delays. Health Canada added 5 more recalls, including labeling issues with Sterile Contro-Vac suction catheters. Fo
Management review is next week. ISO 13485 5.6 requires external signal data as input. Your team hasn't gathered it yet.
Here's what's happening right now: 391 new FDA recalls were posted this week, with 5 new Health Canada recalls. The dialysis convenience kit category shows multiple signals, including Medline's ADD A CATH DIALYSIS KIT and Centurion's CENTRAL LINE INSERTION TRAY, both citing silicone seal failures that could occlude fluid paths. Meanwhile, Edermy LLC's PIE PAK and PIE Trolley System recalls highlight 510(k) clearance issues, and orthopedic implants from Enovis face labeling errors. For your boar
Design controls require you to monitor post-market performance. Where exactly does external signal data fit in your design inputs? You're likely reviewing predicate devices or updating risk management
Here's what's happening right now: 391 new FDA recalls were issued this week, including 5 new signals from Health Canada. Key examples include convenience kits for dialysis maintenance (e.g., Medline ADD A CATH DIALYSIS KIT, Centurion CENTRAL LINE INSERTION TRAY) due to silicone seal issues causing occluded fluid paths, and orthopedic implants like the Reverse Shoulder Prosthesis and EMPOWR 3D KNEE with incorrect labeling. Additionally, there are 26,000 new FDA Adverse Event Reports (MAUDE/MDRs)
Complaint trends are rising for one product family but you can't tell if it's an industry-wide issue or yours alone. You're sifting through internal reports, trying to decide if this warrants a CAPA o
Here's what's happening right now: 391 new FDA recalls were issued this week, with a significant cluster in convenience kits used for dialysis maintenance, including specific SKUs like Medline's ADD A CATH DIALYSIS KIT ECVC8415A and Centurion's CENTRAL LINE INSERTION TRAY DT19810. These recalls cite issues like silicone seal failures leading to occluded fluid paths, which could delay therapy or cause leaks. Additionally, there are 26,000 new FDA Adverse Event Reports (MAUDE/MDRs), with notable s
Your VP asks: 'What's our regulatory exposure across all product lines?' You need a number, not a feeling. You start pulling reports from FDA, Health Canada, and internal systems, knowing this will ta
Here's what's happening right now: 391 new FDA recalls were issued this week, including 5 in convenience kits for dialysis maintenance where silicone seal failures could occlude fluid paths. Health Canada added 5 more recalls, with issues ranging from labeling errors to unauthorized devices. In total, today alone brought 26,590 new regulatory signals across FDA and Health Canada databases. For RA Managers focused on audit preparedness and QMSR compliance, this data highlights critical patterns.
Daily Signal Insight — Feb 25, 2026: High-volume adverse events reveal systemic post-market surveillance gaps in active implantables.
By TrueMedDevice Team · Feb 25, 2026 · 5 min read | Today's 1,010 signals expose critical audit risks where high-volume adverse events for active implantables may indicate inadequate trending and cross-jurisdictional alignment in post-market surveillance systems.
Daily Signal Insight — Feb 24, 2026: Reprocessed Device Recalls and Software Malfunctions Signal Systemic Supplier and Design Control Gaps.
By TrueMedDevice Team · Feb 24, 2026 · 5 min read | Today's data reveals a critical pattern: reprocessed single-use devices and software-driven systems are driving enforcement and adverse events, demanding immediate supplier oversight and design control updates.
Daily Signal Insight — Feb 20, 2026: Enforcement actions reveal systemic supplier and process control failures across high-risk devices.
By TrueMedDevice Team · Feb 20, 2026 · 5 min read | Today's 158 FDA enforcement actions expose critical gaps in supplier qualification, sterile barrier validation, and design verification that cascade into recalls and adverse events.
What Is PMCF and Do I Really Need It? 4-Level Guide (2026)
PMCF (Post-Market Clinical Follow-up) explained at 4 levels — from playground analogy to the MDD-to-MDR evidence crisis. Covers MDCG 2020-7/2020-8 templates, PMCF plan writing, method selection, and why 'not applicable' rarely works with Notified Bodies.
How Do I Monitor Competitor Recalls for PMS? 4-Level Guide (2026)
Competitor recall monitoring explained at 4 levels — from playground analogy to strategic intelligence. Covers which databases to monitor, how to evaluate each signal, the regulatory requirement from EU MDR and FDA, and practical solutions for automated monitoring.
What Will the Inspector Ask About My PMS System? 4-Level Guide (2026)
The exact questions FDA inspectors, EU Notified Body auditors, and MDSAP auditors ask about your PMS system — explained at 4 levels. Includes the 8 documents to have ready, the 'thread-pull' technique inspectors use, and how pre-inspection intelligence targets your weak spots.
What Is a PSUR and How Do I Write One? 4-Level Guide (2026)
PSUR (Periodic Safety Update Report) explained at 4 levels — from a report card analogy to NB review strategy. Covers MDCG 2022-21 template, section-by-section guidance, common mistakes, and practical tips for RA/QA professionals writing their first PSUR.
When Must I Report an Adverse Event? Timelines for Every Country (2026)
Adverse event reporting explained at 4 levels — from simple analogy to multi-jurisdiction filing strategy. Includes the exact reporting timelines for FDA, EU MDR, Health Canada, Japan, Australia, and China, plus the reportability decision tree every RA/QA professional needs.
What Is Post-Market Surveillance? Explained at 4 Levels (2026)
Post-market surveillance explained at 4 levels — from a 5-year-old's analogy to top researcher analysis. Covers why PMS exists, what RA/QA professionals must do daily, the regulations across FDA/EU/HC, and where the field is heading with RWE and AI signal detection.
Unified PMS Compliance Framework: One System for All Markets — The Practical Solution (2026)
How to build a single post-market surveillance system that satisfies FDA, EU MDR, Health Canada, Japan, and other jurisdictions simultaneously. Covers the 8-component architecture, ISO 13485 foundation, MDSAP harmonization, implementation roadmap, ROI analysis, and how automated external monitoring platforms transform RA/QA day-to-day work.
PMS Inspection Preparation and Gap Analysis: What Regulators Actually Look For (2026)
Complete inspection preparation guide for medical device RA/QA professionals. Covers what FDA, EU NB, MDSAP, and Health Canada inspectors check for PMS compliance, the full inspection checklist, gap analysis methodology, PMS maturity model, top 10 audit findings, and how to conduct pre-inspection mock audits.
Internal vs. External Post-Market Surveillance: Complete Operations Guide for RA/QA (2026)
Practical guide explaining the two streams of PMS — internal data (complaints, CAPA, production, service) and external data (regulatory databases, literature, competitor events). Covers daily/weekly/monthly workflows for RA/QA professionals, how to connect both streams, and what regulators inspect.
Global Post-Market Surveillance Requirements: Japan, Australia, China, Brazil, UK, Korea, India (2026)
Comprehensive guide to medical device PMS requirements across 7 jurisdictions — Japan (PMDA), Australia (TGA), China (NMPA), Brazil (ANVISA), UK (MHRA), South Korea (MFDS), and India (CDSCO). Includes reporting timelines, local representative requirements, and MDSAP harmonization.
EU MDR Post-Market Surveillance Requirements: Complete Guide for RA/QA (2026)
Comprehensive guide to post-market surveillance under EU MDR 2017/745 — covering PMS Plans, PSURs, PMCF, vigilance reporting (Articles 83-92), Notified Body audit expectations, and EUDAMED requirements for medical device manufacturers.
FDA vs Health Canada PMS Requirements: Side-by-Side Comparison for Dual-Market Manufacturers
A side-by-side comparison of FDA and Health Canada post-market surveillance requirements for medical device manufacturers selling in both markets — covering reporting obligations, timelines, audit expectations, and harmonization under MDSAP.
Health Canada Post-Market Surveillance Requirements: CMDR, MDSAP, and Medical Device Compliance
Everything RA/QA professionals need to know about Health Canada's post-market surveillance requirements — mandatory problem reporting under CMDR, recall procedures, MDALL licence obligations, and MDSAP audit expectations.
FDA Post-Market Surveillance Requirements: A Complete Guide for Medical Device Manufacturers
A comprehensive reference for RA/QA professionals on FDA post-market surveillance requirements — covering MDR reporting (21 CFR 803), complaint handling, CAPA, trend analysis, and QMSR 2026 changes.
Weekly External PMS Digest (FDA) — Feb 6–13, 2026
This week’s FDA external signals reinforce a familiar RA/QA reality: your audit risk isn’t “missing a recall headline”—it’s failing to prove you reviewed it, assessed relevance, and recorded a decision. A high-quality external PMS system must produce: (1) a clear signal list, (2) relevance triage + rationale, (3) timestamps (Published/Captured/Reviewed), and (4) an exportable evidence pack.
Weekly Digest: Feb 3-10, 2026 - FDA Recalls Surge, Health Canada MDL Updates
This week saw 12 new FDA device recalls including 3 Class I events, plus Health Canada updated 47 medical device listings. Here is what your RA/QA team needs to know.
What Is External Post-Market Surveillance (PMS) and Why Does It Matter?
External PMS means monitoring publicly available regulatory signals for events related to your device. Here is what the standards require and how to build an audit-ready evidence system.
Daily Signal Insight — Mar 25, 2026: FDA enforcement reveals systemic failures in labeling, software, and supplier controls.
By TrueMedDevice Team · Mar 25, 2026 · 5 min read | Today's FDA enforcement actions expose critical gaps in labeling adequacy, software validation, and supplier quality management that could trigger regulatory scrutiny across device categories.
General insight search is useful. Product-specific answers need product context.
Public insight pages can help you understand terms, gather official sources, and prepare better questions. They cannot tell you what is true for your exact product, claims, software scope, evidence set, or market plan without a mapped product-specific workspace.
Guided Q&A and voice input come after the index layer
The next pass can add question-led retrieval and eventually voice input. For now, the goal is simpler: help users find the right page quickly without making them dig through a flat article list.